On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO ...

Biotech company Regeneron (NASDAQ:REGN) reported in Q2 CY2025, with sales up 3.6% year on year to $3.68 billion. Its non-GAAP ...

Regeneron Pharmaceuticals Inc. REGN) on Friday reported second-quarter earnings of $1.39 billion. The Tarrytown, New York-based company said it had profit of $12.81 per share.

U.S. sales of EYLEA HD and EYLEA, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Arc Resources 2Q EPS C$0.68; 2Q Net C$396.1M; 2Q Avg Production 357,228 BOE/Day; 2Q Funds From Operations C$682M, or C$1.17/Share; Boosts 2025 Capital Spending Plan to C$1.85B-C$1.95B; Sees 2025 ...

President Donald Trump escalated his campaign to pressure pharmaceutical companies to lower drug prices, sending letters to 17 of the world’s largest drugmakers demanding they charge the U.S. what oth ...

TCTC Holdings LLC just sold 7,600 shares of CVS Health Corporation (CVS), dialing down its stake by 2.0%, but still holds a ...

Harvest Fund Management Co. Ltd dramatically reduced its stake in Alibaba Group Holding Limited (BABA) by 47.7% in the first quarter, now holding just 72,057 shares valued at approximately $9.5 ...